A blood irradiator is a medical procedure that exposes blood to extremely low-intensity light for therapeutic purposes. This is a very recent treatment when compared to laser treatment, photoepilation, and photodynamic therapy (SVDT), since the former is older and more traditional treatments, whilst the latter is newer approaches. Although the procedure was established in the United States, subsequent research in Russia and Germany has proven that it is just as successful as these other strategies. It is utilized in a variety of diseases where the patient's blood is toxic and must be exposed to light in order to activate the chemo activity that will remove the load from the cells.
Increasing the launch of innovative blood irradiator technologies is projected to boost growth in the global blood irradiator market over the forecast period. Key market players are focusing on R&D operations in order to innovate breakthrough technologies and acquire a competitive advantage in the industry. Rad Source Technologies, for example, debuted the premier X-ray blood irradiator RS 3400 at MEDLAB in June 2021. As a result, such factors are projected to boost the worldwide blood irradiator market over the forecast period.
However, limited population knowledge of the advantages of irradiators in healthcare facilities, along with high irradiator costs, is anticipated to hinder the development of the worldwide blood irradiator market during the forecast period.
Following the onset of the COVID-19 pandemic, the worldwide blood irradiator market saw a dramatic decrease. In an attempt to slow the spread of the virus, several governments imposed strict travel and physical separation laws. These rules significantly affected the worldwide supply chain sector, resulting in a decline in demand for blood irradiators. However, vaccine rollout and falling COVID-19 instances are projected to help in the growth of the worldwide blood irradiator market in the near future.